Coronavirus | Dr. Reddy’s, RDIF get DCGI nod for Sputnik V vaccine clinical trial

Phase 3 trials of the vaccine are already underway in Russia and UAE.

Updated - October 17, 2020 11:51 pm IST

Published - October 17, 2020 05:11 pm IST - HYDERABAD

Sputnik V, the vaccine for COVID-19 developed by Russian company RDIF. AP

Sputnik V, the vaccine for COVID-19 developed by Russian company RDIF. AP

Pharma major Dr. Reddy’s Laboratories and Russia’s sovereign wealth fund RDIF have received approval from the Drugs Controller General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in the country.

This will be a multi-centre and randomised controlled study, which will include safety and immunogenicity study.

Developed by Gamaleya National Research Institute of Epidemiology and Microbiology, Russia, Sputnik V vaccine is the world’s first registered vaccine against COVID-19 based on the human adenoviral vectors platform. The vaccine was registered by Russia’s Health Ministry in August.

The DCGI approval “is a significant development that allows us to commence the clinical trial in India. We are committed to bringing in a safe and efficacious vaccine to combat the pandemic,” Dr. Reddy’s Co-chairman and Managing Director G V Prasad said in a statement issued by the company and RDIF.

Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev said “We are pleased to collaborate with the Indian regulators and in addition to Indian clinical trial data, we will provide safety and immunogenicity study from the Russian phase 3 clinical trial. This data will further strengthen the clinical development of Sputnik V vaccine in India.”

Dr. Reddy’s and Russian Direct Investment Fund (RDIF) had last month announced a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. Under the partnership, RDIF will be supplying 100 million doses of the vaccine to Dr. Reddy’s upon regulatory approval in India.

Sputnik V is currently undergoing phase 3 clinical trial in Russia and the proposed number of subjects is 40,000. Additionally, phase 3 clinical trial of the vaccine has commenced in the UAE last week, the release on Saturday said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.